Effect of omeprazole on plasma concentration and adverse reactions of capecitabine in patients with colon cancer
10.3760/cma.j.issn.0253-3766.2019.09.012
- VernacularTitle: 结直肠癌患者应用奥美拉唑注射液对卡培他滨血药浓度及其毒副反应和疗效的影响
- Author:
Chuangxin LU
1
;
Bowen ZHENG
1
;
Bing BAI
1
;
Jinlong HU
1
;
Sufeng FAN
1
;
Dongfang SHANG
1
;
Di YANG
2
;
Chenglong ZHAO
2
;
Shundong CANG
1
Author Information
1. Department of Oncology, People′s Hospital of Henan Province, Zhengzhou 450003, China
2. Department of Pharmacy, People′s Hospital of Henan Province, Zhengzhou 450003, China
- Publication Type:Clinical Trail
- Keywords:
Colonic neoplasms;
Omeprazole;
Capecitabine;
Plasma drug concentration;
Side effect
- From:
Chinese Journal of Oncology
2019;41(9):708-711
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of omeprazole on plasma concentration, efficacy and adverse reactions of capecitabine in patients with colon cancer.
Methods:Seventy-two patients with colon cancer treated with capecitabine were analysed retrospective. The patients treated with capecitabine combined with omeprazole were identified as experimental group and the capecitabine treatment alone as control group.The differences of blood concentration and the side effects of capecitabine between these two groups were compared.
Results:The plasma concentration of 5-Fluorouracilum in experimental group was (126.25±50.59) μg/ml, without significant difference of (123.09±56.70) μg/ml in control group (P=0.121). The incidence of Ⅲ to Ⅳ degree bone marrow suppression, nausea, vomiting, diarrhea and hand-foot syndrome in experimental group were 13.8%, 0%, 0% and 19.4%, respectively. In control group, the incidence of Ⅲ to Ⅳ degree bone marrow suppression, nausea, vomiting, diarrhea and the hand-foot syndrome were 11.1%, 0%, 0% and 19.4%, respectively, without significant difference of experimental group (P>0.05). The incidence of acid reflux and heartburn in the control group was 72.2%, significantly higher than 44.4% of the experimental group (P<0.05). The objective response rate (ORR) and progression-free survival time (PFS) in these two groups were 30.6% and 33.3%, and 8.0 month and 8.5 month, respectively, without significant difference (P>0.05).
Conclusion:The intravenous omeprazole attenuates reflux and heartburn of colon cancer patients treated with capecitabine, without affecting its plasma concentration and side effects and has no impact on the PFS of these patients.
